simufilam is an investigational drug.
There have been 8 clinical trials for simufilam.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2021.
The most common disease conditions in clinical trials are Alzheimer Disease and [disabled in preview]. The leading clinical trial sponsors are Cassava Sciences, Inc., National Institute on Aging (NIA), and Premier Research International LLC.
There are seven US patents protecting this investigational drug and thirty-seven international patents.